pdf   xlsx method abbreviations

melanoma (ML), pembrolizumab (10mg/kg) versus chemotherapy, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.74 [0.57, 0.96]< 10%1 study (1/-)98.8 %NAnot evaluable crucial-
progression or deaths (PFS) 0.50 [0.39, 0.64]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 8.16 [3.74, 17.80]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

TRAE (any grade) 0.76 [0.45, 1.26]< 10%1 study (1/-)85.8 %NAnot evaluable non important-
TRAE (grade 3-4) 0.54 [0.32, 0.91]< 10%1 study (1/-)98.9 %NAnot evaluable non important-
TRAE leading to death (grade 5) 1.92 [0.06, 57.48]< 10%1 study (1/-)35.6 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 1.65 [0.70, 3.87]< 10%1 study (1/-)12.7 %NAnot evaluable non important-
TRAE leading to discontinuation (grade 3-4) 2.73 [0.85, 8.76]< 10%1 study (1/-)4.6 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Alopecia TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Anaemia TRAE (grade 3-4) 0.05 [0.00, 0.88]< 10%1 study (1/-)97.9 %NAnot evaluable non important-
Arthralgia TRAE (grade 3-4) 0.96 [0.06, 15.39]< 10%1 study (1/-)51.3 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 0.96 [0.06, 15.39]< 10%1 study (1/-)51.3 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 2.90 [0.30, 28.13]< 10%1 study (1/-)18.1 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 1.28 [0.28, 5.81]< 10%1 study (1/-)37.5 %NAnot evaluable non important-
Dry skin TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 0.23 [0.05, 1.10]< 10%1 study (1/-)96.7 %NAnot evaluable non important-
Hepatitis TRAE (grade 3-4) 3.85 [0.17, 86.06]< 10%1 study (1/-)20.0 %NAnot evaluable non important-
Hyperthyroidism TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Hypophysitis TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Leucopenia TRAE (grade 3-4) 0.07 [0.00, 1.17]< 10%1 study (1/-)96.7 %NAnot evaluable non important-
Maculopapular rash TRAE (grade 3-4) 1.92 [0.06, 57.48]< 10%1 study (1/-)35.6 %NAnot evaluable non important-
Myalgia TRAE (grade 3-4) 0.48 [0.02, 14.29]< 10%1 study (1/-)66.3 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.23 [0.03, 2.12]< 10%1 study (1/-)90.0 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 0.08 [0.00, 1.39]< 10%1 study (1/-)95.7 %NAnot evaluable non important-
Pancreatitis TRAE (grade 3-4) 1.92 [0.06, 57.48]< 10%1 study (1/-)35.6 %NAnot evaluable non important-
Paraesthesia TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Peripheral neuropathy TRAE (grade 3-4) 0.24 [0.01, 5.29]< 10%1 study (1/-)81.5 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 5.81 [0.29, 116.90]< 10%1 study (1/-)12.8 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Thrombocytopenia TRAE (grade 3-4) 0.23 [0.03, 2.12]< 10%1 study (1/-)90.0 %NAnot evaluable non important-
Uveitis TRAE (grade 3-4) 1.92 [0.06, 57.48]< 10%1 study (1/-)35.6 %NAnot evaluable non important-
Vitiligo TRAE (grade 3-4) 0.96 [0.02, 48.41]< 10%1 study (1/-)50.9 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 0.23 [0.03, 2.12]< 10%1 study (1/-)90.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons